Charles River Laboratories (CRL) and Captain T Cell said Monday that they have entered into a plasmid DNA and retrovirus vector production program deal.
Captain T Cell will use plasmid and viral vector contract development and manufacturing organization services under Charles River's cell and gene therapy accelerator program, the companies said.
This will support Captain T Cell's preparation to manufacture a T cell receptor T cell therapy for solid tumor patients for a phase 1 trial, the companies added.
Price: 208.55, Change: -0.92, Percent Change: -0.44
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments